Advertisement

Cipla gets USFDA nod for rare genetic condition treatment drug

Follow The Hawk on Google News+ Follow

Advertisement

New Delhi: Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Icatibant Injectable, indicated for treatment of acute attacks of hereditary angioedema - a rare genetic condition - in adults.

Cipla''s Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire''s Firazyr, the company said in a regulatory filing.

Advertisement

The firm said "it has received final approval for its abbreviated new drug application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration".

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Quoting IQVIA (IMS Health) data, Cipla said Firazyr and its generic equivalents had US sales of approximately USD 270 million for the 12-month period ending May 2020.

Shares of Cipla were trading 0.49 per cent higher at Rs 641.25 apiece on the BSE.

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST